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http://dx.doi.org/10.1016/j.stemcr.2016.08.004SUMMARYBlood vessels are formed through vasculogenesis, followed by remodeling of the endothelial network through angiogenesis.Many events
that occur during embryonic vascular development are recapitulated during adult neoangiogenesis, which is critical to tumor growth and
metastasis. Current antiangiogenic tumor therapies, based largely on targeting the vascular endothelial growth factor pathway, show
limited clinical benefits, thus necessitating the discovery of alternative targets. Here we report the development of a robust embryonic
stem cell-based vascular differentiation assay amenable to small-molecule screens to identify novel modulators of angiogenesis. In
this context, RSK and TTK were identified as angiogenic modulators. Inhibition of these pathways inhibited angiogenesis in embryoid
bodies and human umbilical vein endothelial cells. Furthermore, inhibition of RSK and TTK reduced tumor growth, vascular density, and
improved survival in an in vivo Lewis lung carcinoma mouse model. Our study suggests that RSK and TTK are potential targets for anti-
angiogenic therapy, and provides an assay system for further pathway screens.INTRODUCTION
Pluripotent embryonic stem cells (ESCs) provide essential
tools for understanding mammalian developmental pro-
cesses, as they can differentiate in vitro into many tissues
in a normal developmental manner (Keller, 2005; Solter,
2006). These cells are amenable to high-throughput screens
using RNAi or small-molecule libraries to dissect molecular
pathways (Ding and Buchholz, 2006; Xu et al., 2008). Early
vascular and hematopoietic differentiation of ESCs has
been extensively studied (Keller, 2005), making these path-
ways particularly attractive for large-scale screens.
Blood vessels are first formed through vasculogenesis,
whereby angioblasts (endothelial precursors) aggregate in
the developing embryo to form a primitive network of
endothelial tubes. This network is later remodeled through
a complex process termed angiogenesis, which includes
sprouting of new blood vessels, to form the mature circula-
tory network (Rossant and Howard, 2002). Major break-
throughs in our understanding of vascular development
and remodeling have arisen from characterization of
vascular mutant phenotypes in mice. Vascular endothelial
growth factor (VEGF), acting through the FLK-1/VEGF re-
ceptor 2 (VEGFR2), is crucial for blood vessel formation
and development (Carmeliet et al., 1996; Shalaby et al.,
1995). NOTCH/DLL4 signaling plays a critical role in
branching/sprouting morphogenesis, whereby loss ofStem Cell Re
This is an open access artiNOTCH signaling leads to excess tip cell formation and
non-productive vessel development (Hellstrom et al.,
2007). Impaired vascular development was also reported
for mutations in ANG/TIE, platelet-derived growth factor
(PDGF), transforming growth factor b (TGF-b), EFN, HH,
and PLXN/SEMA signaling pathways (reviewed by Rossant
and Howard, 2002).
Many signaling pathways required during embryonic
vascular development are also essential during adult neo-
angiogenesis (Carmeliet, 2003). Adult neovascularization
occurs in many physiological and pathological settings,
such as wound healing (Ruiter et al., 1993), recovery from
myocardial infarction (Chung et al., 2002), tumor growth,
and metastasis (Ruiter et al., 1993). There is increasing in-
terest in using modulators of angiogenesis to treat cancer
(Ferrara, 2004). Currently antiangiogenic therapy has two
opposing target pathways, the VEGF/FLK-1 and DLL4/
NOTCH pathways (Kuhnert et al., 2011). The new genera-
tion of antiangiogenic drugs that have arisen from an un-
derstanding of vascular developmental biology, such as
bevacizumab (anti-VEGF) (Ferrara et al., 2005), have
demonstrated some efficacy in cancer patients, but cause
serious side effects and frequent relapses (Kerbel, 2008).
Similar results have been obtained from inhibition of the
NOTCH/DLL4 pathway (Andersson and Lendahl, 2014),
thus necessitating the discovery of alternative therapeutic
targets.ports j Vol. 7 j 787–801 j October 11, 2016 j ª 2016 The Author(s). 787
cle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Development and Validation of
ESC-Based Vascular Differentiation Assay
(A) Undifferentiated Flk1-eGFP ESCs under
phase contrast (left panel) and GFP filter
(right panel). Scale bar, 100 mm.
(B) Flk1-eGFP ESCs were aggregated in sus-
pension in hanging drops for 4 days and
observed under phase contrast (left panel)
and GFP filter (right panel). Scale bar,
100 mm.
(C) Schematic representation of vascular
differentiation assay method.
(D) PECAM-1 staining of Flk1-eGFP-derived
EBs embedded in collagen type I gel
and treated with VEGF (50 ng/mL), bFGF
(100 ng/mL), IL-6 (10 ng/mL), and EPO
(2 U/mL). Scale bar, 500 mm.
(E) Validation of the assay using two
small-molecule inhibitors, a NOTCH inhibi-
tor (L685, 5 mM), and an FLK-1 inhibitor
(SU5416, 4 mM). Scale bar, 500 mm.
(F and G) Cellomics was used to quantify
FLK-1+ sprouts (F) and FLK-1 expression
(measured as total fluorescent intensity) (G).
(H) Quantification of FLK-1+ sprouts ob-
tained by manual counts. Data are mean ±
SEM, n R 3. *p < 0.0001, statistically sig-
nificant compared with DMSO control; **p <
0.0001, statistically significant compared
with DMSO and VEGF + DMSO controls.
(I and J) Characterization of vascular
sprouts of Flk1-eGFP-derived EBs treated as
indicated. (I) Anti-a-SMA staining (white
arrows point to mural cells). Scale bar,
25 mm. (J) Anti-Dll4 staining (white arrows
point to tip cells, gray arrows point to stalk
cells). Scale bar, 25 mm.
See also Figure S1.To this end we have developed a robust, highly repro-
ducible, mouse ESC-based vascular differentiation assay
that is sensitive to both inhibition and promotion of
vascular sprouting as well as to changes in vessel
morphology. Using our embryoid body (EB)-based assay,
we undertook a kinase inhibitor screen to identify small
molecules that could block or enhance blood vessel
sprouting morphogenesis. The screen yielded numerous
hits, which we validated in vitro and subsequently
tested for in vivo antiangiogenic activity in a Lewis
lung (LL/2) carcinoma model. We have identified RSK
and TTK as potential targets for antiangiogenic tumor
therapy, and provide an assay system for further pathway
screens.788 Stem Cell Reports j Vol. 7 j 787–801 j October 11, 2016RESULTS
Development of a Robust, and Reproducible Vascular
Differentiation Assay Using ESCs
We have previously reported the generation of ESCs
whereby EGFP was inserted into the Flk-1 locus, and
showed that this reporter faithfully recapitulates all areas
of FLK-1 expression (Ema et al., 2006). As predicted, no
EGFPwasobserved in theundifferentiatedESCs (Figure 1A),
and high levels of EGFP were observed when ESCs were
differentiated into EBs (Figure 1B). To optimize the vascular
differentiation assay (Figure 1C), we aggregated Flk1-eGFP
ESCs in suspension as hanging drops to form EBs. Different
cell concentrations, types ofmatrices, anddifferent days for
embedding of EBs were tested (see Supplemental Experi-
mental Procedures). We determined that EBs generated
from 200 cells and embedded in collagen type I gels at day
4 gave the most consistent and reproducible results. There
was no significant difference in the number of FLK-1 posi-
tive (FLK-1+) sprouts between EBs treated with VEGF only
and EBs treated with VEGF in the presence of one or more
of the previously established angiogenic growth factors
(basic fibroblast growth factor [bFGF], interleukin-6 [IL-6],
and erythropoietin [EPO]) (Feraud et al., 2001) (Figure S1A),
suggesting that VEGF alone accounts for themajority of the
angiogenic response and is the only factor required in our
assay. PECAM-1 staining showed nearly complete overlap
with the Flk1-eGFP reporter both in the primary vascular
plexus formed in the EBs and the angiogenic sprouts ex-
tending from the EBs (Figure 1D). We also determined
that the optimal point for quantification of FLK-1+ sprouts
was day 7 after embedding, as abundant sprouting was
observed and both increases and decreases in angiogenesis
would be readily measurable (Figures S1B, S1C, and 1E–
1H).Using theCellomicsArrayScanplatform,weoptimized
theneuronalprofiling algorithmtoobjectivelyquantify the
number of FLK-1+ sprouts and the total expression of FLK-1
(measured as total fluorescent intensity). This algorithm
demonstrated that our assay can detect both increases and
decreases in angiogenesis in response to signaling pathway
inhibitors (Figures 1F, 1G, and S1C). Visual inspection
confirmed automated counts (Figure 1H). The reproduc-
ibility of VEGF + DMSO control, as measured by FLK-1+
sprout quantification, is shown in Figures S1D and S1E.
Treatment with g-secretase inhibitor (L685,458; referred
to hereafter as L685) in the presence of VEGF significantly
increased angiogenic sprouting by R113.4% (Figures 1E,
1F, and1H) and total FLK-1 expressionby150.6%compared
withVEGF+DMSOcontrol (Figures 1Eand1G), as expected
for a NOTCH pathway inhibitor. Treatment with an FLK-1
inhibitor (SU5416) significantly decreased VEGF-induced
angiogenic sprouting by R82.9% (Figures 1E, 1F, and 1H)
and FLK-1 expression by 71% (Figures 1E and 1G). Treat-
ment with L685 or SU5416 in the absence of VEGF resulted
in a similar number of FLK-1+ sprouts and expression as
DMSO controls (p not significant), suggesting that very
little angiogenesis occurs in the absence of VEGF (Figures
1E–1H). Given these findings, all inhibitors were added
in the presence of VEGF. To characterize the sprouts,
we stained them with a-smooth muscle actin (a-SMA) or
DLL4, markers for mural cells and tip cells, respectively.
VEGF + DMSO-treated EBs showedmural cells surrounding
the sprouts (Figure 1I) and high levels of DLL4 in tip cells,
whereas DLL4 staining was reduced or absent in the stalk
cells (Figure 1J). VEGF + L685-treated EBs showed reduced
mural cells (Figure 1I) and decreased DLL4 staining in tip
cells (Figure 1J), consistent with previous studies on the ef-fect of NOTCH inhibition onmural cell differentiation and
DLL4 expression (Arima et al., 2011). Somemural cells were
observed in DMSO- and VEGF + SU5416-treated EBs (Fig-
ure 1I), but DLL4 was absent (Figure 1J).
We also demonstrate that our assay, in addition to being
sensitive to increases and decreases in vessel sprouting, can
also detect morphological changes in vessel shape (Figures
S1F and S1G).
Small-Molecule Kinome Screen for Modulators of
Angiogenesis
To identify novel modulators of angiogenesis, we used
our assay to screen a kinase small-molecule inhibitor library
(Figures 2A and 2B) consisting of 480 compounds. Hits were
registered as quantitative deviations from VEGF control
cultures (Figure S2), since VEGF was also added to every
well containing the inhibitors. Automated quantification
successfully distinguished neutral events and increases,
although distinction between inhibitory and toxic hits had
to be confirmed by visual inspection. Representative images
of the hits and reproducibility of the phenotypes between
replicates are shown inFigures2C–2N.Graphical representa-
tion of the hits is shown in Figure 2O. A hit was considered
real/specific if the majority of compounds that were known
to inhibit thatparticular target in the library showedactivity.
Table 1 lists hits thatmet these criteria. A few compounds re-
sulted in a NOTCH loss-of-function-like phenotype. For
example, a PKC inhibitor resulted in excessive sprouting;
however, since themajorityof the library compounds target-
ing PKC showed no effect on angiogenesis, the phenotype
wasdeemed tobeanoff-target effect andnotpursued further
(Table S1). Our library screen detected 40 of the 44 com-
pounds that target FLK-1, thus further validating our
vascular assay and screening methodology. The majority of
hits were validated with dose curves (Figure S3). Our screen
identifiedmanykinaseswithwell-established roles in angio-
genesis such as FLK-1(Shalaby et al., 1995), TIE2 (Partanen
et al., 1996), PDGFRb (PDGF receptor b) (Rossant and Ho-
ward, 2002; Zhang et al., 2009), ALK (anaplastic lymphoma
kinase) (Di Paolo et al., 2011), ALK5 (TGFBR1) (Rossant and
Howard, 2002), BMK1 (ERK5) (Hayashi et al., 2005; Pi et al.,
2005), FGFR (FGFreceptor) (Bonoetal., 2013), IGFR(insulin-
like growth factor receptor) (Bid et al., 2012), MEK1/2
(Giroux et al., 1999), and ERK1/2 (Srinivasan et al., 2009),
among others (Table 1). Importantly, we also identified
RSK andTTK in the screen; kinases that have not beenprevi-
ously shown to regulate angiogenesis. Our inhibitoryhits all
fall intooneof six signalingpathways (Figure2P).Criteria for
pursuing hits are summarized in Figure S2.
Compound and Target Hit Validation
To validate RSK as a hit, we performed a dose-response
curve using the inhibitors identified by our screen,Stem Cell Reports j Vol. 7 j 787–801 j October 11, 2016 789
Figure 2. Kinome Small-Molecule Library
Screen
(A) Schematic of the methodology for
screening the small-molecule library. The
screen was done blinded.
(B) Controls and phenotypes observed in
library. Scale bar, 300 mm.
(C–N) Representative examples of hits and
reproducibility of the phenotype between
replicates. Scale bar, 300 mm.
(O) Graphical summary of hits. n = 4 tech-
nical replicates; data are normalized to
VEGF + DMSO controls and expressed as
mean ± SEM.
(P) All hits in the screen fall into one of the
six outlined pathways. Red indicates tar-
gets identified in the screen.
See also Figures S2 and S3; Tables S1 and S3.BIX-RSK2 (referred to as compound 15 in the study by Fryer
et al., 2012) (Figure 3A) and BI-D1870 (Figure 3B). These in-
hibitors have previously been shown to be selective (Fryer
et al., 2012; Sapkota et al., 2007). It is important to note
that BI-D1870 at high concentrations (10 mM or above)
can have off-target effects, although this inhibitor was
shown to be selective when used at 2.5 mMand lower (Roffe
et al., 2015; Sapkota et al., 2007). RSKs (RSK1–4) are a family
of serine/threonine kinases that share 75%–80% amino
acid identity and are activated by the MAPK pathway
through a series of phosphorylation events (Anjum and
Blenis, 2008). Interestingly, RSK protein levels are elevated
in several tumor types (Clark et al., 2005; Smith et al.,
2005). Downstream substrates of RSKs include CREB,
c-FOS, IkB, LKB1, and RPS6 (Anjum and Blenis, 2008;790 Stem Cell Reports j Vol. 7 j 787–801 j October 11, 2016Romeo et al., 2012). Notably, LKB1 is required for vascular
development (Londesborough et al., 2008). We confirmed,
through western blot analysis, that BI-D1870 and BIX-
RSK2 were targeting the RSK/LKB1 pathway, which is
downstream of MEK/ERK. Treatment with VEGF in the
presence of 2 mM of either the MEK1/2 inhibitor (GSK-
1120212), ERK1/2 inhibitor (ERK2), or RSK inhibitors (BI-
D1870, BIX-RSK2) resulted in a significant decrease in
p-RSK levels (R46.6% decrease, p < 0.01) and p-LKB1
(R46.4% decrease, p < 0.0001) compared with the
VEGF + DMSO control (Figure 3C). A schematic of the
pathway is depicted in Figure 2P. VEGF + DMSO-treated
EBs also showed slightly elevated total RSK and total
LKB1 levels (Figure 3C), perhaps due to stabilization of
these proteins in response to phosphorylation/activation.
Table 1. Hits Identified in Vascular Screen
Categories Drug Target
Number of Inhibitors
that Hit Target/Total
Number of Inhibitors
of that Target in Library
Number of Dose
Curves (Validation) References (Angiogenesis)
Cell surface receptors ALK 3/4 Di Paolo et al., 2011; Safina et al., 2007
ALK5 8/10 1 Rossant and Howard, 2002
c-MET 13/20 1 Lu and Bergers, 2013
FGFR 11/13 2 Bono et al., 2013
FLK1 40/44 2 Ferrara et al., 2005; Shalaby et al., 1995
FLT1/FLT4/KIT 6/6 1 Sleijfer et al., 2009
FLT3/FLK2, SYK 22/24, 4/4 2 Kazerounian et al., 2011
IGFR 4/7 3 Bid et al., 2012
PDGFRb 26/36 Zhang et al., 2009
TIE2 5/5 1 Partanen et al., 1996
MAPK pathway ERK2 4/6 1 Srinivasan et al., 2009
ERK5 1/2 1 Hayashi et al., 2005; Pi et al., 2005
FAK 3/4 1 Tavora et al., 2010
MEK1/2 12/15 2 Giroux et al., 1999
PDK1 3/5 1 Tawaramoto et al., 2012
RAF 11/17 2 Wimmer et al., 2012
SRC/FYN/ABL/LCK 5/7 4 Schenone et al., 2007
TAK1 (MAP3K7) 3/3 Jadrich et al., 2006
p90 ribosomal S6K (RSK) 2/2 2
JAK/STAT pathway JAK 13/20 1 Xin et al., 2011
Cell-cycle regulators AURORA 19/21 Romain et al., 2014
CDC7 1/1 Shi et al., 2012
CDK2/CYCLIN A 13/20 Chen et al., 2000
MPS1 (TTK) 1/1 1
CHK1/2 8/11 2
PLK1 6/8 2 Gomes et al., 2013
SPK1 2/3 1 Duan et al., 2007
See also Figure S3.To validate TTK (MPS1) as a bona fide hit, we performed
dose-response analysis using AZ3146 (Figure 3D), a TTK in-
hibitor thatwas identified inour screen andhasbeen shown
to be selective (Hewitt et al., 2010). TTK, a dual-specificity
kinase that phosphorylates serine, threonine, and tyrosine
residues, is an essential component of the spindle assembly
checkpoint and is required for chromosomal alignmentduring mitosis (Liu and Winey, 2012). TTK expression is
elevated in multiple cancers (breast, lung, and gastric can-
cer) (Liu and Winey, 2012). Downstream targets of TTK
include CHK2 (Liu and Winey, 2012) and SMAD2/3 (Zhu
et al., 2007). Notably, SMAD2 has been implicated in angio-
genesis (Assis et al., 2015; Pen et al., 2008). Our data showed
that treatment with VEGF + AZ3146 resulted in a 73.5%Stem Cell Reports j Vol. 7 j 787–801 j October 11, 2016 791
Figure 3. Validation of RSK and TTK In-
hibitors in EBs
EBs embedded in collagen type I were
treated with DMSO, VEGF (50 ng/mL) +
DMSO, or VEGF (50 ng/mL) in the presence
of inhibitors and dosed twice over a 7-day
period. On day 7, EBs were either fixed,
imaged and quantified for dose-curve
analysis, or lysed in RIPA buffer for western
blot analysis. Asterisk denotes statistical
significance compared with DMSO control.
(A) Dose-curve analysis of BIX-RSK2.
(B) Dose-curve analysis of BI-D1870.
(C) Western blot analysis showing the effect
of 2 mM of various inhibitors on phosphor-
ylated and total levels of LKB1 and RSK.
Data were normalized to b-ACTIN. Data are
mean ± SEM, n = 5. *p < 0.01 for normalized
P-RSK/total RSK, and *p < 0.0001 for
normalized P-LKB1/total LKB1.
(D) Dose-curve analysis of AZ3146.
(E) Western blot analysis showing the effect
of 2 mM AZ3146 on phosphorylated and
total levels of SMAD2. Data are mean ± SEM,
n = 6. *p < 0.0001.
For dose-curve analysis (A, B, and D), values
were normalized to VEGF + DMSO controls.
Drug doses were log transformed. Data are
mean ± SEM, n = 4 technical replicates.
Scale bars, 300 mm. See also Table S2.decrease (p < 0.0001) in SMAD2phosphorylation compared
with VEGF + DMSO control (Figure 3E).
The Effect of RSK and TTK Inhibitors on Disruption of
Angiogenic Sprouts
To determine whether BI-D1870, BIX-RSK2, and AZ3146
can disrupt preformed angiogenic sprouts, we treated EBs
with VEGF for 6 or 7 days before addition of inhibitors, as
abundant angiogenesis was observed at these time points
(Figures S1B and 1E–1H). BI-D1870, BIX-RSK2, AZ3146,
or the known FLK-1 inhibitor SU5416 (Fong et al., 1999)
were then added in the presence of VEGF on days 6 or 7.
Cultures were maintained for three additional days and
fixed. BI-D1870 (Figure 4B), BIX-RSK2 (Figure 4C), and
SU5416 (Figure 4E) resulted in significantly reduced792 Stem Cell Reports j Vol. 7 j 787–801 j October 11, 2016FLK-1+ sprouts (R57.2%, p < 0.0001) compared with the
VEGF + DMSO controls (Figure 4A). AZ3146 resulted in a
significant decrease (21.3%) in FLK-1+ sprouts when added
on day 6 but not on day 7 (Figure 4D). All four drugs signif-
icantly decreased angiogenesis by R78.1% (p < 0.0001)
when added in the presence of VEGF on day 1 post embed-
ding (Figures 4B–4E).
The Effect of RSK and TTK Inhibitors on HUVEC Tube
Formation and Disruption of Preformed Tubes
We sought to validate our top hits in a secondary human-
relevant cell-based assay, using humanumbilical vein endo-
thelial cells (HUVECs). This also allowed us to determine
whether inhibition of RSK and TTK, which are expressed
inmultiple cell types, hadadirect effect onendothelial cells.
Figure 4. Effect of RSK and TTK Inhibi-
tors on Preformed EB Angiogenic Sprouts
RSK and TTK inhibitors (2 mM) or SU5416
(4 mM) were added either at day 1 post
embedding, in the presence of VEGF
(50 ng/mL), or added on days 6 or 7 post
VEGF treatment, also in the presence of
50 ng/mL VEGF, and imaged on days 9 or
10 post embedding, respectively, and the
number of FLK-1+ sprouts quantified.
(A) VEGF + DMSO controls.
(B) Effect of BI-D1870.
(C) Effect of BIX-RSK2.
(D) Effect of AZ3146.
(E) Effect of SU5416.
Inh, Inhibitors. Data were normalized to
VEGF + DMSO controls. Data are mean ±
SEM, n R 3. *p < 0.0001 compared with
VEGF + DMSO controls. Scale bars, 300 mm.
See also Figure S1B.No difference was observed in network morphology be-
tween DMSO and VEGF controls, suggesting that complete
medium which was not supplemented with VEGF but con-
tained bFGF was sufficient to promote network formation
(Figures 5A and 5B). BI-D1870, BIX-RSK2, AZ3146, and
SU5416 resulted in disruption of the networks compared
with the DMSO or VEGF controls (Figure 5A). Furthermore,
when these drugs were added 13 hr post plating, after the
networks were already established, they were also able to
disrupt the preformed HUVEC tubes (Figure 5B).
The Effect of RSK and TTK Inhibitors on LL/2
Cells In Vitro and Analysis of In Vivo Exposure to
These Drugs
The LL/2 model was chosen to examine the effect of our
hits on tumor angiogenesis, as it is a widely used modelfor studying angiogenesis (Eklund et al., 2013) and is
effective in predicting clinical benefit (Chow and Eck-
hardt, 2007). As BIX-RSK2 is not commercially available,
we focused on BI-D1870 and AZ3146 for the remainder of
our study. BI-D1870 and AZ3146 had no cytotoxic effects
on the LL/2 cells in vitro except at very high doses (Fig-
ure S4A). The IC50 values showed that BI-D1870 dis-
played 33.25-fold selectivity, and AZ3146 showed 11.55-
fold selectivity for inhibition of EB angiogenic sprouting
over LL/2 cell growth inhibition (Table S2). In vivo expo-
sure analysis showed that a dose of 50 mg/kg for BI-
D1870 and AZ3146 via intraperitoneal injection resulted
in plasma concentrations well above the IC50 for inhibit-
ing angiogenesis of the EBs and well below the IC50 for
having any effect on the LL/2 cells (Table S2). Further-
more, these doses were well tolerated by the mice, withStem Cell Reports j Vol. 7 j 787–801 j October 11, 2016 793
Figure 5. Effect of RSK and TTK Inhibi-
tors on HUVEC Tube Formation and on
Preformed HUVEC Tube Networks
(A and B) represent two parts of the same
experiment and share DMSO and VEGF +
DMSO controls. HUVECs were plated on
Geltrex, and either (A) immediately treated
with complete HUVEC medium containing
DMSO, or VEGF (30 ng/mL) + DMSO, or 2 mM
BI-D1870, BIX-RSK2, or AZ3146, or 4 mM
SU5416, and imaged at 13 hr (scale bar,
200 mm), 21 hr (scale bar, 200 mm) and
23 hr (scale bar, 500 mm) post seeding; or
(B) treated 13 hr post plating with 2 mM
BI-D1870, BIX-RSK2, or AZ3146, or 4 mM
SU5416, and imaged at 21 hr (8 hr drug
treatment; scale bar, 200 mm) and 23 hr
(10 hr drug treatment; scale bar, 500 mm)
post seeding. Calcein-AM was added at the
end of the experiment and is shown as green
fluorescence in the bottom panels of (A)
and (B).no significant changes in weight or behavior observed
(Figure S4B).
The Effect of the RSK and TTK Inhibitors on Survival,
Tumor Growth, and Angiogenesis In Vivo
To test for the efficacy of these compounds on tumor
growth and angiogenesis in vivo, we treated LL/2 tumor-
bearing mice with vehicle, BI-D1870, AZ3146, or SU5416
via intraperitoneal injections daily for 14 days (Figure 6A).
BI-D1870 and AZ3146 significantly improved survival
(Figure 6B) and significantly decreased tumor volume
from days 8 and 7 onward, respectively, with a 37% and
32% decrease in tumor volume by day 14 post treatment
(Figure 6C, p < 0.05). PECAM-1 staining of tumors excised
at day 14 post treatment showed that BI-D1870 and
AZ3146 significantly decreased vessel density (38% and
35%, respectively, p < 0.01) (Figure 6D). Conversely, the
well-established antiangiogenic FLK-1 inhibitor SU5416794 Stem Cell Reports j Vol. 7 j 787–801 j October 11, 2016had no effect on survival (Figure 6B) or tumor volume (Fig-
ure 6C), and did not significantly decrease vessel density
(Figure 6D). The dose of SU5416 we used has been reported
to be the maximum effective tolerated dose for that
compound (Fong et al., 1999). Quantification of vessel
density in normal host tissue showed no significant differ-
ence between vehicle-treated and drug-treated groups
(Figure S4C).
To determine the effect of these compounds on
signaling, we performed western blot analysis on tumors.
BI-D1870 and SU5416 had no effect on RSK (Figure 6E) or
LKB1 phosphorylation (Figure 6F) but resulted in a signifi-
cant decrease (R64.2%, p < 0.001) in phosphorylation of
RPS6 (Figure 6G), a target of RSK (Anjum and Blenis,
2008; Romeo et al., 2012) and the VEGF pathway (Jeong
et al., 2014). AZ3146 significantly decreased (35.8%, p <
0.05) phosphorylation of SMAD2, a target of TTK (Zhu
et al., 2007) (Figure 6H). Both RPS6 (Hayashi et al., 2005)
and SMAD2 (Assis et al., 2015; Pen et al., 2008) have previ-
ously been associated with angiogenesis.DISCUSSION
We have developed an unbiased, robust, and reproducible
three-dimensional EB-based vascular differentiation assay
that is amenable to screening for modulators of angiogen-
esis. The EB-based vascular differentiation assay in collagen
matrix offers advantages over the widely used HUVEC/
Matrigel assay as well other in vitro angiogenic models in
that it uniquely allows the study of both vasculogenesis
and angiogenesis (Feraud et al., 2001). The EB assay, unlike
the HUVEC assay, models the complex in vivo interactions
between endothelial cells and their support cells, which is
essential for recapitulating normal vessel formation (Fer-
aud et al., 2001). The assay is sensitive to both increases
and decreases in vessel sprouting as well as reading out
morphological changes in vessel shape, as exemplified by
an additional screen that showed treatment with all-trans
retinoic acid resulted in the ballooning of vascular sprouts
(Figures S1F and S1G).
Previous reports have described ESC-based differentia-
tion in collagen gels to study the developmental events
of vasculogenesis and angiogenesis (Feraud et al., 2001;
Hermant et al., 2007). However, these were not optimized
for the assessment of more fundamental aspects of vessel
induction, patterning, and remodeling, nor were these
assays standardized into a 96-well plate format suitable
for screening. In some previous reports, EB size was not
controlled (Feraud et al., 2001; Hermant et al., 2007),
which is essential for obtaining the consistency and
reproducibility required in a screen. Additionally in these
assays, multiple growth factors for vascular induction
were used (Feraud et al., 2001; Hermant et al., 2007), or
high concentrations of cells were used for EB formation
(Jakobsson et al., 2006), which increases variability.
Building on the foundation of these studies, we have stan-
dardized and simplified the culture system and employed a
fluorescent reporter to allow easy monitoring of morpho-
genesis, thus producing a more robust assay suitable for
drug screens in the mouse system. Future studies using
human pluripotent cell lines, aided by the advances in
genome-editing technologies, will allow the use of more
robust reporter lines for endothelial differentiation in the
human system.
Our assay was validated using NOTCH and FLK-1 inhib-
itors, since disruption of these pathways results in visible
alterations in angiogenesis (Hellstrom et al., 2007; Shalaby
et al., 1995). By screening a small-molecule kinome library
we expected a large number of hits, given that the vascu-
lature is very sensitive to signaling pathway disruption.We identified many kinase targets with well-established
roles in angiogenesis, including RTKs (VEGFR, PDGFR,
FGFR, TIE2, FLT-3, c-MET, and IGF1R) as well as their
downstream effectors including RAF, MEK, and ERK,
further validating our screen. JAK, ALK, ALK5, and
AURORA were also hits and have well-established roles
in regulating angiogenesis. It is important to note that
despite the fact that our screen is designed to detect
both promoters and inhibitors of angiogenesis, all of our
validated hits inhibit angiogenesis. It is possible that the
NOTCH pathway may be unique in causing excessive
sprouting. Interestingly, inhibition of ALK1 has also
been shown to lead to excessive angiogenic sprouting,
which was attributed to cooperation of ALK1 with the
NOTCH pathway (Kerr et al., 2015). An additional screen
of a more broad-based library similarly showed that only
NOTCH inhibitors resulted in excessive angiogenic sprout-
ing (data not shown). Screening of this second library
showed that our assay is sensitive to phenotypic changes
that were measurable beyond just increases or decreases
in the number of FLK-1+ sprouts (i.e., retinoids had no
major effect on sprout number but caused morphological
changes in vessel shape). This suggests that the complete
landscape of target space that can be explored with this
assay is still to be determined.
We identified RSK and TTK as angiogenic modulators.
We showed that treatment of EBs or HUVECS with BI-
D1870 and BIX-RSK2, the selective RSK inhibitors, or
with AZ3146, the selective TTK inhibitor, inhibited angio-
genic sprouts in EBs and network formation in HUVECs,
and disrupted the preformed HUVEC tubes and the pre-
formed EB angiogenic sprouts. It is important to note
that these inhibitors disrupted network formation in
HUVECs induced by bFGF without VEGF supplementa-
tion, suggesting that they are downstream of multiple
proangiogenic pathways. Western blot analysis of EBs
showed that TTK and RSK inhibitors resulted in a signifi-
cant decrease in phosphorylation of the downstream tar-
gets, SMAD2 and LKB1, respectively, in association with
the observed decrease in angiogenesis. A previous report
has suggested the involvement of RSK in angiogenesis,
although no direct evidence was provided (Hayashi et al.,
2005). Our study provides direct proof that RSK and TTK
regulate angiogenesis.
Future studies using genetic approaches involving the
generation of ESC lines with inducible gene knockout of
RSK and TTK need to be performed to further validate our
hits.
To determine whether the inhibition of RSK and TTK in-
hibits neovascularization in vivo, we gavemice LL/2 tumor
grafts. Both BI-D1870 and AZ3146, used at doses deter-
mined to be non-toxic to animals, significantly improved
survival, inhibited tumor growth, and decreased vascularStem Cell Reports j Vol. 7 j 787–801 j October 11, 2016 795
Figure 6. Determination of the Efficacy of BI-D1870 and AZ3146 on a Lewis Lung Tumor Model In Vivo
Lewis lung cells (1 3 106) were injected subcutaneously in the right flank of 6- to 9-week-old C57Bl/6Crl mice. Mice were randomized
into one of four treatment groups: vehicle (n = 24), BI-D1870 (n = 20), AZ3146 (n = 18), and SU5416 (n = 10). Treatments were
administered via intraperitoneal (i.p) injection daily for 14 days. Asterisk denotes statistical significance compared with vehicle-treated
controls.
(A) Schematic of the methodology for the in vivo study.
(B) Survival was evaluated using the Kaplan-Meier method. *p < 0.05.
(legend continued on next page)
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density. In contrast, SU5416 had no effect on survival. In
agreement with a recent study (Ogawara et al., 2014),
SU5416 did not affect LL/2 tumor graft growth nor signifi-
cantly decreased vessel density. In contrast to Ogawara’s
and our studies, there is a previous report showing that
SU5416 significantly inhibited tumor angiogenesis and
metastasis of an LL/2 model (Cuneo et al., 2007). This
discrepancy may be due to the fact that Cuneo et al.
(2007) began treatment with SU5416 either immediately
or 1 hr after injecting LL/2 cells, whereas in our study
and that of Ogawara et al. (2014), we began treatment
once tumors reached a minimal volume of 100 mm3.
Therefore, in the LL/2 model SU5416 may be effective in
inhibiting host vessels from infiltrating the tumor, but inef-
fective once the tumor is well vascularized. Ogawara et al.
(2014) showed that SU5416 significantly reduced tumor
growth in B16 and C-26 with no effect on LL/2 tumor
grafts. This was attributed to high levels of VEGF within
B16 and C-26 tumors, compared with LL/2 tumors, sug-
gesting that VEGF does not play a major role in the angio-
genesis of LL/2 tumors; instead, other proangiogenic fac-
tors, such as bFGF, are responsible for angiogenesis/tumor
growth in LL/2. Other studies showed that inhibition of
VEGF in tumors can lead to upregulation of bFGF and other
proangiogenic factors (Lu and Bergers, 2013) to overcome
VEGF inhibition. Interestingly, RSK is a downstream target
of bFGF (Czaplinska et al., 2014) and VEGF (Seko et al.,
1998), which constitute two major proangiogenic path-
ways involved in tumor growth (Lu and Bergers, 2013).
Although many of the signaling events involved in
developmental angiogenesis are also involved in tumor
angiogenesis, there are distinct differences between these
two processes, which lead to dysfunctionality of the tumor
vasculature. In the case of tumors, tissue disorganization,
high enzymatic activity, overproduction of growth factors
and extracellular matrix components, and changes in pH
and oxygen in the tumor environment lead to detachment
of pericytes, leakiness of vessels, and loss of vascular integ-
rity (Jin and Jakobsson, 2012). This could explain why
AZ3146 and BI-D1870 resulted in a significant decrease in
vessel density in the tumor but had no effect on the vessel(C) Tumor volume was measured over 14 days. AZ3146 and BI-D1870 re
8 onward, respectively, compared with vehicle-treated controls. Data
(D) Tumors were excised on day 14, fixed, embedded, sectioned, and
panel (scale bar, 100 mm). Vessel quantification was performed on the m
end of the study (day 14 post treatment) and is shown in the graph on
n = 8 (AZ3146), n = 2 (SU5416). *p < 0.01.
(E–H) Western blot analysis was performed on tumors harvested on day
are mean ± SEM, p not significant. (F) Levels of phosphorylated and
phosphorylated and total RPS6. Data are mean ± SEM, *p < 0.001. (H
*p < 0.05.
See also Figure S4 and Table S2.density in normal host tissue. This, along with the lack of
change in body weight and behavior, indicates that these
drugs at the doses used were not toxic.
We also investigated the effect of AZ3146 and BI-D1870
on the downstream phosphorylation of targets in tumors.
AZ3146 significantly decreased SMAD2 phosphorylation
in tumors. SMAD2 can positively regulate VEGF release in
various tumor cell lines (Seystahl et al., 2015) and plays a
role in angiogenesis (Assis et al., 2015; Pen et al., 2008).
BI-D1870 had no effect on LKB1 phosphorylation in tu-
mors, unlike EBs. This finding is not surprising, as LKB1
has been shown to promote physiological angiogenesis
(Londesborough et al., 2008), whereas in cancer cells it
acts as a tumor suppressor and inhibits angiogenesis
(Zhuang et al., 2006). However, treatment with BI-D1870
significantly decreased RPS6 phosphorylation in tumors.
Interestingly, decreased phosphorylation of RPS6 has
been correlated with decreased tumor angiogenesis (Haya-
shi et al., 2005).
In summary, we have developed and validated a robust
vascular differentiation assay from ESCs that can be used
to screen for modulators of angiogenesis. This in vitro
assay identified RSK and TTK as components of vascular
signaling pathways. Inhibition of these pathways in vivo
in an LL/2 tumor mouse model increased survival, in-
hibited tumor growth, and decreased angiogenesis associ-
ated with decreased RPS6 and SMAD2 phosphorylation.
Extension of this screening approach to a broader spec-
trum of molecular targets may provide new insights into
the regulation of vascular development and uncover
potential new targets for the therapeutic modulation of
angiogenesis.EXPERIMENTAL PROCEDURES
Reagents were purchased from Invitrogen unless otherwise
specified.
Cell Lines and Culture
Flk1-eGFP mouse ESCs (Ema et al., 2006) were cultured on
mitotically inactivated mouse embryonic fibroblasts (MEFs) insulted in a significant decrease in tumor volume from day 7 and day
are mean ± SEM. *p < 0.05.
stained with PECAM-1. Representative images are shown in the left
ajority and in some cases all of the mice/group that survived to the
the right. Data are mean ± SEM, n = 6 (vehicle), n = 10 (BI-D1870),
14 post treatment. (E) Levels of phosphorylated and total RSK. Data
total LKB1. Data are mean ± SEM, p not significant. (G) Levels of
) Levels of phosphorylated and total SMAD2. Data are mean ± SEM,
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ESC media (ES-DMEM) consisting of high-glucose DMEM, 2 mM
GlutaMax, 0.15 mM 1-thioglycerol (Sigma-Aldrich), 0.1 mM
nonessential amino acids, 1 mM sodium pyruvate, 1,000 U/mL
LIF (Chemicon), 50 U/mL penicillin-streptomycin, and 15%
ESC-qualified fetal bovine serum (FBS).
HUVECs were cultured in Medium 200PRF supplemented with
the LSGS Kit.
LL/2 cells (ATCC) were maintained in high-glucose DMEM
(ATCC) supplemented with 10% FBS.
Optimized Vascular Differentiation Assay and Kinome
Inhibitor Screen
MEF-depleted Flk1-eGFP cells (104 cells/mL) were aggregated in
suspension (20-mL hanging drops) for 4 days to form EBs in differ-
entiation media consisting of Iscove’s medium (IMDM, Sigma-
Aldrich), 1.6 mM GlutaMax, 0.081 mM nonessential amino acids,
0.081 mM 2-mercaptoethanol (Sigma-Aldrich), 10% FBS, 50 U/mL
penicillin-streptomycin, and 50 mg/mL ascorbic acid (Sigma-Al-
drich). On day 4, EBs were embedded in 2 mg/mL rat tail collagen
type I (BDBiosciences) gels in the individualwells of a 96-well plate
and incubated at 37C. The following day differentiation media
alone or containing DMSO or VEGF (50 ng/mL, R&D Systems),
or VEGF (50 ng/mL) in the presence of other growth factors
(100 ng/mL bFGF [R&D]; 10 ng/mL IL-6; and/or 2 U/mL EPO [pro-
vided by the Keller laboratory]), or 50 ng/mLVEGF in the presence
of 5 mM L685,458 (EMD Biosciences) or 4 mM SU5416 (Sigma-
Aldrich) or 2 mM kinase library inhibitors (provided by Ontario
Institute for Cancer Research, see Table S3 for the compound list)
were added and themedia replenished on day 3. The EBswere fixed
in 4% formaldehyde (Polysciences) on day 7 (unless otherwise
noted) and the number of FLK-1+ sprouts and total fluorescent
intensity were measured using the Cellomics VTI (Zeiss Axio
Observer.Z1 microscope, ORCA-ER camera) (Thermo Fisher) plat-
form with a modified neuronal profiling algorithm (see Supple-
mental Experimental Procedures).
Immunohistochemistry of EBs in collagen gels, dose-curve vali-
dation of hits, western blot analysis, HUVEC tube formation assay
and disruption of preformed tubes, cytotoxicity assay, and in vivo
exposure analysis are described in detail in the Supplemental
Experimental Procedures.
Mouse Tumor Grafts and In Vivo Drug Studies
All procedures involving animals were performed in agreement
with the Canadian Council for Animal Care (CCAC) guidelines at
the Toronto Center for Phenogenomics. Female C57BL/6NCrl
mice (6–9 weeks old) were injected subcutaneously in the right
flank with 1 3 106 LL/2 cells in 0.2 mL of serum-free DMEM.
Tumor volume was calculated using the formula: (length 3
width)2 3 0.5. Mice were randomized into one of four treatment
groups where the average tumor volume ± SEM per group at the
initiation of treatment was as follows: vehicle (129.8 ± 6.6 mm3,
n = 24), BI-D1870 (122 ± 7.6 mm3, n = 20), AZ3146 (128.6 ±
10.5 mm3, n = 18), and SU5416 (124.1 ± 6.8 mm3, n = 10). Treat-
ments were administered via intraperitoneal injection daily for
14 days or until animal endpoint. BI-D1870 and AZ3146 were
administered at 50 mg/kg, and SU5416 at 25 mg/kg. Tumors were
calipered daily for volume assessment. The experiment was stag-798 Stem Cell Reports j Vol. 7 j 787–801 j October 11, 2016gered to allow proper handling/monitoring of mice. Mice were
euthanized if tumors reached endpoint as outlined by the CCAC
(ulcerated tumor, tumor volume R1.7 cm3, or tumor mass = 5%
of body weight), or if they displayed poor health. Otherwise mice
were euthanized after the last drug dose on day 14. Tumors were
excised, and a portion was fixed in 10% formalin and embedded
in paraffin. The remainder was cut into pieces and snap-frozen.
Immunohistochemistry and Microvascular Density
Quantification of Tumors and Adjacent Normal Tissue
Tumor sections (5 mm), two sections per tumor, were stained with
anti-PECAM-1 (M-20) (Santa Cruz Biotechnology). Bound anti-
body was detected with ImmPRESS (Peroxidase) Polymer anti-rab-
bit immunoglobulin reagent (Vector Laboratories) and visualized
using ImmPACT DAB peroxidase (HRP) substrate (Vector Labs).
Mayer’s hematoxylin (Sigma-Aldrich) was used as a counterstain.
Slides were digitized using an Aperio ScanScope XT scanner
(Leica), and computer-aided image analysis was performed and
manually checked for quality assurance. Regions of interest were
identified with an algorithm that distinguishes tumor from
stroma and (peri-)necrotic regions. The vessel density within
the tumor region, as well as in the adjacent normal tissue, was
quantified using the Definiens Tissue Studio software platform
(Definiens). Quantification was done while blinded to the treat-
ment groups.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism, via un-
paired Student’s t tests, or one-way ANOVA followed by New-
man-Keuls post tests. Data are presented as mean ± SEM. Survival
was evaluated by the Kaplan-Meier method. n represents the num-
ber of independent experiments, unless otherwise noted. p < 0.05
was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and three tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2016.08.004.
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